Novartis AG ADR (NVS)vsTriSalus Life Sciences Inc. (TLSI)
NVS
Novartis AG ADR
$148.38
-0.42%
HEALTHCARE · Cap: $273.77B
TLSI
TriSalus Life Sciences Inc.
$3.30
+3.77%
HEALTHCARE · Cap: $223.56M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 125957% more annual revenue ($56.58B vs $44.88M). NVS leads profitability with a 23.9% profit margin vs -60.9%. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
TLSI
Avoid16
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Intrinsic value data unavailable for TLSI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
No standout strengths identified
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Trading at 15.7x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -496.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : TLSI
TLSI has a balanced fundamental profile.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : TLSI
The primary concerns for TLSI are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 2.69 is elevated, increasing financial risk.
Key Dynamics to Monitor
NVS profiles as a declining stock while TLSI is a turnaround play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 16/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →TriSalus Life Sciences Inc.
HEALTHCARE · MEDICAL DEVICES · USA
TriSalus Life Sciences Inc. (TLSI) is an innovative biopharmaceutical company focused on revolutionizing cancer treatment through its proprietary localized drug delivery systems. By enhancing the effectiveness of immuno-oncology agents and overcoming distribution challenges within tumor microenvironments, TriSalus is dedicated to improving therapeutic outcomes for cancer patients. With a promising pipeline of clinical programs, the company aims to meet the urgent demand for advanced cancer therapies. Positioned strategically within the dynamic oncology landscape, TriSalus is poised for significant impact as it seeks to expand access to its groundbreaking treatments.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?